The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Open accessAbstract
Background and Aims Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the FAT-MASH model was used, as this model reproducibly recapitulates the stages of progression of human MASH that include advanced fibrosis and tumors along with changes in the gut microbiome.14,33,34”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“These functions normally contribute to tissue repair under homeostatic conditions, but sustained activation in chronic liver diseases drives fibrosis, especially in MASH (41) where they are detectable by expression of desmin and alpha smooth muscle actin (αSMA) using immunofluorescence, and by conservation of gene expression based on single-cell RNA-seq (42-46).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
In the citing paper
“Our laboratory uses a simple rodent model of MASH, the “FAT-MASH” mouse, which robustly develops Fibrosis and Tumors, features of advanced disease, after 24 weeks of a Western diet combined with a small weekly dose of the liver toxin CCl4 (45).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationMaeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160
Cited by
Sorted by citations
Items 501–587 of 587
Development of liver organoids from NASH model mice and their application to drug discovery
Yamamoto, H., Usui, T., & Sasaki, K. (2021) · Folia Pharmacologica Japonica · doi:10.1254/fpj.21027
Zhang, Y., Yang, X., Bi, T., Wu, X., Wang, L., Ren, Y., Ou, Y., Xie, C., Li, K., Ran, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3990739
Bhattacharya, D., Becker, C., Readhead, B. P., Goossens, N., Buros, J. L., Fiel, M. I., Cousens, L. P., Magnusson, B., Backmark, A., Hicks, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-386482/v1
Self-citation(2020) · Вестник Российского государственного медицинского университета · doi:10.24075/brsmu.2020-03
Mwangi, S. M., Li, G., Balasubramaniam, A., Merlin, D., Dawson, P. A., Jang, Y. C., Hart, C. M., Czaja, M. J., & Sriniva, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1677830/v1
Establishment of Non-Alcoholic Steatohepatitis Mouse Model
戴, 冠. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121744
Angeborene und erworbene Immunität im Kontext der nichtalkoholischen Fettlebererkrankung
Heinrich, B. (2022) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1055/a-1993-3519
Cholesterol-associated Locus EHBP1 Protects against NASH FibrosisPreprint
Ma, F., Longo, M., Huang, X., Meroni, M., Prakash, S., Paolini, E., Bhattacharya, D., Wang, S., Wang, X., Mughal, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.08.548218
Self-citationEslami, Z., Kandi, Y. M., Norouzi, A., Moghanlou, A. E., Arabi, M. S., Kazeminejad, V., Alarzi, S. S. H., Saidi, A., & Joshaghani, H. (2022) · شهباز. · doi:10.61186/mlj.16.3.7 · Cited by 1
Song, F., & Chen, Z. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i24.989
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Suresh, D., Gunaseelan, B., Srinivas, A. N., Bharadwaj, A., Joseph, J., Megha, M., Varghese, T., Satish, S., Suvarna, D., Santhekadur, P. K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.23.595466
Liver Systems in Safety Pharmacology
Mahajan, V. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_64-1
Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital
Kraus, N., Uschner, F. E., Moeslein, M., Schierwagen, R., Gu, W., Brol, M. J., Fürst, E., Grünewald, I., Lotersztajn, S., Rautou, P., et al. (2024) · Cells · doi:10.3390/cells13201707
Liver Systems in Safety Pharmacology
Mahajan, V. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_64
Homan, E. A., Gilani, A., Rubio‐Navarro, A., Johnson, M. A., Schaepkens, O. M., Cortada, È., de Lima, R. P., Stoll, L., & Lo, J. C. (2024) · eLife · doi:10.7554/elife.100708.2
Personnaz, J., Cannizzo, L., Martin, C. M. P., Desquesnes, A., Sotin, M., DaSilva, J., Perrier, P., Guillou, H., & Kautz, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.628701
Александровна, П. В., Orlyakhina, D. A., Petrova, V. D., Karev, V. E., Ivkin, D. Y., Михайловна, Н. С., & Okovityi, S. V. (2024) · Drug development & registration · doi:10.33380/2305-2066-2025-14-1-1994 · Cited by 1
Xiao, L., Qin, L., Deng, S., Ahmed, J. Z., & Huang, B. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5062517
Goonetilleke, M., Correia, J., Chen, Y., McDonald, H., Chan, S. T., Inocencio, I. M., Cross, J., Greening, D. W., Simpson, I. A., Sievert, W., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5679779/v1
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma
Tsakiridis, E. E., Ahmadi, E., Gautam, J., She, Y. R. H., Fayyazi, R., Lally, J., Wang, S. J. H., Pastena, F. D., Valvano, C. M., Rosso, D. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101354
Guan, W.-X., Zhuo-Lan, Luo, X.-J., Gao, J.-X., & Bai, C.-X. (2025) · Scientific Reports · doi:10.1038/s41598-025-93583-4
Andriianov, V. S., Malyutina, A., Panferov, E., Karabelsky, A. V., Ivanov, R. A., Minskaia, E., & Reshetnikov, V. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199432
Sarr, O., Thompson, J. A., Lam, N. L. H., Kiser, P. K., & Regnault, T. R. H. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168054
Targeting macrophage iron in nonalcoholic steatohepatitis
Collins, J. F. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00197.2025
Zhang, B., Tu, J., Ban, Z., Peng, Y., Zhou, Y., Yu, Q.-M., & Tan, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118460
Liver Zonation Disruption Fuels Hepatocellular Carcinoma in Chronic Liver DiseasePreprint
Yang, S. B., Tullio, F. D., Yang, L., Cogliati, B., Schnidrig, D., Benjak, A., Roshan, S., Almeida, J. I., Li, L. Y., Ma, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.06.692782
Xie, Y., Huang, Y., Li, Z.-Y., Jiang, W., Shi, N.-X., Lu, Y., Cao, G., Yin, Z., & Lin, X.-J. (2024) · Figshare · doi:10.6084/m9.figshare.26717691
Wang, Y., Tai, Y.-L., Way, G. W., Zeng, J., Zhao, D., Su, L., Jiang, X., Jackson, K. G., Wang, X., Gurley, E. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21321418
Wang, Y., Yang, Y., Zhao, Z., Sun, H., Luo, D., Huttad, L., Zhang, B., & Han, B. (2022) · Figshare · doi:10.6084/m9.figshare.19571936
Wang, Y., Yang, Y., Zhao, Z., Sun, H., Luo, D., Huttad, L., Zhang, B., & Han, B. (2022) · Figshare · doi:10.6084/m9.figshare.19571945
Xie, Y., Huang, Y., Li, Z.-Y., Jiang, W., Shi, N.-X., Lu, Y., Cao, G., Yin, Z., & Lin, X.-J. (2024) · Figshare · doi:10.6084/m9.figshare.26717694
Wang, Y., Yang, Y., Zhao, Z., Sun, H., Luo, D., Huttad, L., Zhang, B., & Han, B. (2022) · Figshare · doi:10.6084/m9.figshare.19571939
Liang, J., Gu, L., Liu, X., Yan, X., Bi, X., Fan, X., Zhou, J., Lu, S., Luo, L., & Yin, Z. (2022) · Figshare · doi:10.6084/m9.figshare.19606700
Xie, Y., Huang, Y., Li, Z.-Y., Jiang, W., Shi, N.-X., Lu, Y., Cao, G., Yin, Z., & Lin, X.-J. (2024) · Figshare · doi:10.6084/m9.figshare.25779361
Xie, Y., Huang, Y., Li, Z.-Y., Jiang, W., Shi, N.-X., Lu, Y., Cao, G., Yin, Z., & Lin, X.-J. (2024) · Figshare · doi:10.6084/m9.figshare.25779485
da Silva, R. P., & Eudy, B. J. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.101349
Ma, N., Song, J., & Yang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1735042
Wang, Y., WANG, Z., Yan, G., Peng, C., Chen, L., Yan, R., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70495 · Cited by 1
Zhao, C., Luan, Y., Yang, D., Yan, S., Zhang, J., Liu, F., Chen, X., Lan, T., Gong, X., Rao, H., et al. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110303
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Zheng, X., Zhang, Z., Jiao, X., Mu, M., Liu, A. Y., Huang, Y., Wu, W., Liao, C., Jiang, Y., Liang, W., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109721
Mancini, M. C., Adams, E. R., Burk, D. H., Carmouche, R. P., Webb, S., Staszkiewicz, J., Salbaum, J. M., Mackintosh, S. G., & Heden, T. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.06.710198
Wei, L., Deng, S., Li, S., Zhang, Q., Mao, X., Pan, D., Huang, S., & Yang, X. (2026) · Current Drug Metabolism · doi:10.2174/0113892002444655260213065337 · Cited by 1
Role of autophagy in liver sinusoidal endothelial cells on nonalcoholic steatohepatitis
Hammoutène, A. (2018) · theses.fr (ABES) · doi:10.70675/bce7a140z3574z43dbza40ez1cd3403ed525
Rôle des cellules endothéliales dans le carcinome hépatocellulaire associé au syndrome métabolique
Laouirem, S. (2019) · theses.fr (ABES) · doi:10.70675/8139d5c7zb3b1z466az837az2b9408b374a8
Role of RIPK1 in the survival and death of hepatocytes : its involvement in murine hepatitis models
Farooq, M. (2019) · theses.fr (ABES) · doi:10.70675/5fe7950dz1147z4d64z9b9bz87bfd1d3ae35
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
Hobeika, C. (2022) · theses.fr (ABES) · doi:10.70675/4c247323z584fz42b6za12cze7812b01da9e
Coopération oncogénique et effets métaboliques de FGF19 dans le carcinome hépatocellulaire
Bedoya, J. U. (2021) · theses.fr (ABES) · doi:10.70675/d2df913bz04e7z457dzb21dzf6ae23303e0c
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Rôle de REG3A dans la maladie métabolique du foie d'origine nutritionnelle
Nguyen, T.-S. (2024) · theses.fr (ABES) · doi:10.70675/2c0ffdcfz96ccz43b0z8e03zb358f83e528d
Chen, Y., Zhang, J., Wang, W., Zhang, M., Wang, Y., Chen, Y., Zhou, T., Chen, J., Lu, X., Chen, J., et al. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103307
Cevallos, K. A. A., Abad, J. L., Babiy, B., Sacristán, S., Hidalgo-Llorente, A., Senra, Y., Busto, R., Martı́nez-Botas, J., Abad-Montero, D., Bujons, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03686
Lee, Y., Kim, I. S., Kim, J. W., Kim, M. K., Chae, Y. G., Choi, C. S., Kwon, O. S., Kim, Y. I., Kim, J. H., Chung, D. H., et al. (2026) · Free Radical Research · doi:10.1080/10715762.2026.2668102
Self-citationLi, Y. Z., Qu, S., Deng, S., Liu, C., Liang, Y., Wang, L., Chen, L., Zhu, Q., Wu, Q., Liu, T., et al. (2026) · Science of Traditional Chinese Medicine · doi:10.1097/st9.0000000000000112
A Mouse in vivo Model Mimicking MASH-Related HCC Pathogenesis
Zheng, T., Pei, Z., Cui, E., Zhu, L., Du, J., & Ling, C. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s593754
Li, J. N., Li, H., Dong, L., Yao, L., Dong, X., Guo, Y., Pu, C., Wang, A., & Chen, J. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00439-0
Wu, A., Ou, W., Chen, D., Wang, Y. H., Lin, G., Yang, J., Hong, Y., Li, M., Yang, Q., Lin, C., et al. (2026) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073446908260305080457
Mancini, M. C., Adams, E. R., Burk, D. H., Carmouche, R. P., Webb, S. M., Staszkiewicz, J., Salbaum, J. M., Mackintosh, S. G., & Heden, T. D. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00441-6
A Paracrine Dietary Lipid Axis Constrains Antitumor Immunity in Liver CancerPreprint
Ciobu, N., Kumari, R., Kumar, J. S., Balaseviciute, U., Iftesum, M., Mitchell, J., Ruiz, J., Flowers, S., Nishikawa, K., Cano-Segarra, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734592
Wu, J., Li, S., Huang, Z., He, L., Guo, Y., Cheng, Y., Wang, Y., Du, Y., Xu, L., & Huang, F. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.06.011
Zhou, J., Yang, C., Guo, Y., Zhao, L., Lu, S., Luo, L., Zhou, D., & Yin, Z. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01173-6
Bariatric surgery resolves MASH by enhancing MAT1A-dependent one-carbon metabolism
Tang, B., Shen, Q., Yuan, J. P., Huang, X., Shao, Y., zhu, N., Guo, H. H., Cao, H., Wang, H., Wang, H. W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75822-y
Mei, Y., Cai, W., Huang, Q., Chen, Q., Lin, Y., Chen, Y., Xin, C., Lu, C., Chen, Z., Chen, X., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11119-y
Александровна, П. В., Максимовна, М. Т., Doroshchuk, K. S., Fedorova, A. A., Karev, V. E., Samarich, A. S., Евгеньевич, К. В., Karelina, E. A., Muraveva, N. A., Pyatchenkov, M. O., et al. (2026) · Drug development & registration · doi:10.33380/2305-2066-2026-15-3-2389
Xu, Y., Zhang, S., Wang, K., Zhang, C., Li, J., Li, J., Wang, L., & Li, Y. (2026) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2026.2716134
An, P., Wu, L., & Wang, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119883
Kim, H., Kim, G., Yeon, H., Yang, D.-Y., Lee, S. G., An, T. H., Oh, S. Y., Yoon, S., Kim, J., Choi, J., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01838-5
Amino acid transporters in hepatocellular carcinoma: Gatekeepers of metabolic reprogramming
Immanuel, J. R., Shankaran, Z. S., Mani, M., Paul, S. F. D., Ashok, B. S., Chand, L., & Walter, C. E. J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12759-x
Goodman, A. Z., Stauffer, W. T., & Gallay, P. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358225
Wu, L.-L., Bai, Y., Su, E.-Z., Cao, F.-L., Fang, X.-Y., & Zhao, L.-G. (2026) · Nutrients · doi:10.3390/nu18183062
GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytesPreprint
Kotikalapudi, N., Ramachandran, D., Zhou, E. Y., Howard, J. A., Vieira, C. J., Chen, W., HSU, S., Shin, K. C., Naz, S., Jiang, Z. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752693
Haq, A. T. A., Yang, P.-P., Shen, P.-C., Tseng, H., Chen, L.-M., Chen, M. A., Yuh, C.-H., & Hsu, H.-L. (2026) · Research Square · doi:10.21203/rs.3.rs-10952514/v1
Yamaguchi, K. D., Yamanoi, K., Ogura, J., Koike, A., Umemiya, M., Higashiyama, N., Kou, K., Inayama, Y., Mizuno, R., Miyamoto, T., et al. (2026) · Cancer Reports · doi:10.1002/cnr2.70702
Yuan, M., Ye, J., Sun, X., Tong, Z., Wang, T., 谭仁香, & Wu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179413
Præstholm, S. M., Correia, J. C., Justiniano, R. H., da Rocha, A. L., Leuchtmann, A. B., Sereiva, T., Porsmyr‐Palmertz, M., Rothamel, K., Kamińska, D., Ganji, R. S., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102457
Nandawadekar, L. D., Sharma, N., Panneerselvam, S., Ramesh, E., Patekar, R. R., Routholla, G., Bharate, S. B., Andugulapati, S. B., & Reddy, D. S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01449
Metadata
- Authors
- Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., & Friedman, S. L.
- Affiliations
- Tanabe Pharma Corporation (Japan) (JP)
- Icahn School of Medicine at Mount Sinai (US)
- Mount Sinai Hospital (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 69
- Issue
- 2
- Pages
- 385-395
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6054570
- OpenAlex
- W2790198401
- Cited by
- 583
- References
- 56
- Citations by year
- 2026: 65 · 2025: 86 · 2024: 90 · 2023: 91 · 2022: 93 · 2021: 62 · 2020: 52 · 2019: 34 · 2018: 10
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-01)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- NIH
- NIDDK (DK099558)
- European Commission (ERC-2014-AdG-671231)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, mouse model, Western diet, carbon tetrachloride, liver fibrosis, hepatocellular carcinoma, liver transcriptome, immune abnormalities, preclinical drug testing
- MeSH terms
- Animals, Carbon Tetrachloride, Disease Models, Animal, Fatty Liver, Inflammation, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Reproducibility of Results, Disease Progression, Gene Expression Profiling, Mice, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
